

## NPCA Newsletter, January 2018

### Annual Report 2017

The [NPCA Annual Report 2017](#) was launched on the **23rd November 2017** during the British Association of Urological Surgeons, Section of Oncology meeting. Professor Noel Clarke, NPCA Urological Clinical Lead, presented an update on the Audit during the conference.

The report presents the results for patients diagnosed between 1st April 2015 to 31st March 2016 in England and Wales including:

- Trust and Health Board participation in the NPCA, including data completeness and data quality
- The characteristics of all men newly diagnosed with prostate cancer, information regarding diagnosis and staging, and initial treatments in England and Wales
- The variation in disease presentation in England and Wales
- The performance of NHS Providers in England across the patient pathway from diagnosis and treatment allocation to the outcomes following treatment

For the first time, the NPCA presents validated performance indicators capturing treatment-related toxicity, which allow the quality of radical treatments delivered in England to be measured and compared between providers. This enables areas where quality improvement is required to be identified.

A patient summary of the report will be published on the new NPCA website (see below).

### NPCA website

A new NPCA website is currently in development. On this website, you will be able to view the data quality and key performance indicators for your Trust and compare with the national results.

You will be notified in advance of the launch, which is planned for the beginning of March.

### Annual Report 2018

The NPCA 2018 Annual Report will be published in Autumn 2018 for patients diagnosed with prostate cancer between **1st April 2016 and 31st March 2017**. Please ensure that your data submissions are complete by **Monday 19th March 2018**.

Please contact your **local NCRAS Data Improvement Lead** should you have any queries related to your data submissions.

Thank you to all urological and uro-oncological colleagues, and their clinical and non-clinical teams, who collect and submit data for the audit. Your support is key to enabling the NPCA to evaluate the care that men receive following a diagnosis of prostate cancer and whether this care reflects recommended guidelines and quality standards.

## Clinical Outcomes Publication 2018: unit level results

The following treatment-related performance indicators will be published on [NHS Choices](#) week commencing 5th February 2018:

For each hospital **Trust that carries out radical prostate cancer surgery:**

- The proportion of patients who had an emergency readmission within 90 days of radical prostatectomy
- The proportion of men experiencing a severe urinary complication requiring an intervention following radical prostatectomy

For each hospital **Trust that provides radiotherapy:**

- The proportion of men experiencing a severe bowel complication requiring an intervention following external beam radiotherapy

These performance indicators, adjusted for patient case mix, were published in the Annual Report 2017. The detection and management of outliers was carried out according to the [NPCA Outlier Policy](#).

One hospital was flagged as a potential 'outlier' but after further analysis this centre was shown to have readmission rates consistent with the rest of the country.

## NPCA data items in COSD V8.0

Three of the existing NPCA data items will be in the new version of COSD that will be collected from 1 April 2018. The data items are in the following table with old and new data item numbers listed. **It is essential that these data items remain in the NPCA data submission**, along with the other NPCA and COSD data items. These data items have been highlighted to Somerset Cancer Register and Infoflex as part of the COSD V8.0 discussions. If you use another Cancer Management System, you may have a few changes to make:

- Change the NPCA item numbers to the new COSD item numbers for the three data items
- Change/map 0 to 7 for the 'Not Applicable' definition for UR15410
- Add '9 - Not Known' definition for UR15420

Data item No.	Data Item Section	Data Item Name	Data Item Description	Format	National Code	National code definition
UR15410 Currently NPCA03	UROLOGICAL - DIAGNOSIS - PROSTATE	PROSTATE BI- OPSY TECH- NIQUE	The type of prostate biopsy technique performed before treatment	an1	1	Transrectal sampling biopsy
					2	Transrectal saturation biopsy
					3	Perineal sampling biopsy
					4	Perineal template mapping biopsy
					7	Not Applicable (No biopsy done)
					8	Other
					9	Not known
UR15420 Currently BAUS Q20	UROLOGICAL - TREATMENT - PROSTATE	PROCEDURE - NERVE SPAR- ING	Extent of surgical nerve sparing. This is also required for the BAUS audit (BAUS Q20)	an1	1	Bilateral
					2	Unilateral
					3	None
					9	Not Known
UR15430 Currently NPCA11	UROLOGICAL - TREATMENT - PROSTATE	RADICAL PROS- TATECTOMY MARGIN STA- TUS	The surgical margin status following radical prostatectomy	an1	1	Negative Margins
					2	Positive Margins <3mm in length
					3	Positive Margins ≥3mm in length
					4	Positive Margins, length unknown
					9	Not Known